Author Details :
Volume : 5, Issue : 4, Year : 2020
Article Page : 405-409
Introduction: Fine needle aspiration cytology (FNAC) is a safe, cost effective and accurate means of evaluating thyroid lesions. Using The Bethesda system of reporting thyroid cytopathology (TBSRTC), cytopathologist can communicate thyroid FNA interpretations to the referring physician which is clinically useful.
Aim: To describe the cytomorphological features of FNAC and correlate with thyroid hormone status in patients presented with diffuse swelling/solitary nodule of thyroid.
Materials and Methods: A total of 50 cases of thyroid FNA s studied for 10 months duration from Dec 2019 to Sept 2020 in the Department of pathology, KBNIMS, Gulbarga. The lesions were evaluated cytologically, categorised according to the Bethesda system for reporting thyroid cytopathology and correlated with Thyroid hormone profile.
Results: Out of 50 cases of thyroid FNAs studied, Females were most commonly affected and most common age group affected was middle aged individuals (31-40yrs). Bethesda Category 2 benign lesions were most commonly present in our study. Benign follicular nodule was more common among non neoplastic lesions. Most of the benign and malignant lesions were euthyroid and hypothyroidism is seen in hashimoto thyroiditis in most cases.
Conclusion: FNAC is a simple and cost effective diagnostic modality for thyroid lesions with high specificity and accuracy. cytological analysis in conjunction with thyroid hormone profile, helps clinicians determine the course of therapy in effective management of patients with thyroid lesions.
Keywords: Bethesda category, FNAC, Thyroid lesions, T3, T4, TSH.
How to cite : Lalitha Reddy G, Begum Z, Patil A, Bethesda reporting of thyroid FNACS with T3, T4, TSH correlation in a medical college of North Karnataka. IP J Diagn Pathol Oncol 2020;5(4):405-409
Copyright © 2020 by author(s) and IP J Diagn Pathol Oncol. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)